I don’t think that you should invest based on the Democratic or Republican conventions being televised. The truth of the matter is that the affect of a President’s party or the convention to select him is too infrequent to have any statistical significance. There is no way that a Confident Investor could surmise that a specific stock will rise or fall based solely on the political party of the President of the United States of America.

Even though I don’t think it is a wise investment strategy, it is interesting to engage in trivia discussions over wine, coffee, or the water cooler with fellow investors. So in that spirit, I reference a recent article on MarketWatch.  I am only putting two of the paragraphs here but it is probably worth your effort to click over and read the entire article.

In the 16 presidential election years since 1948, the S&P 500-stock index has risen during 11 Republican conventions, as measured from the start to the end of the convention, according to a report by S&P Capital IQ. In contrast, stocks notched gains during only seven Democratic conventions.

When markets reacted favorably during one convention, they tended to drop during the opposing party’s convention. That suggests that if markets rise this week while Republicans are meeting, the odds are, stocks might drop when Democrats hold their convention in Charlotte, N.C., Sept. 3 to 6, says Sam Stovall, chief equity strategist for S&P Capital IQ.

Company name Kraft Foods Inc.
Stock ticker KFT
Live stock price [stckqut]KFT[/stckqut]
P/E compared to competitors Fair
MANAGEMENT EXECUTION
Employee productivity Fair
Sales growth Good
EPS growth Good
P/E growth Poor
EBIT growth Poor
ANALYSIS
Confident Investor Rating Fair
Target stock price (TWCA growth scenario) $36.39
Target stock price (averages with growth) $41.32
Target stock price (averages with no growth) $35.15
Target stock price (manual assumptions) $35.06

The following company description is from Google Finance: http://www.google.com/finance?q=kft

Kraft Foods Inc. (Kraft Foods) manufactures and markets packaged food products, including biscuits, confectionery, beverages, cheese, convenient meals and various packaged grocery products. The Company sells its products to consumers in approximately 170 countries. Kraft Foods operates in three segments: Kraft Foods North America, Kraft Foods Europe and Kraft Foods Developing Markets. At December 31, 2010, Kraft Foods had operations in more than 75 countries and made its products at 223 manufacturing and processing facilities worldwide. At December 31, 2010, its portfolio included 11 brands Oreo, Nabisco and LU biscuits; Milka and Cadbury chocolates; Trident gum; Jacobs and Maxwell House coffees; Philadelphia cream cheeses; Kraft cheeses, dinners and dressings, and Oscar Mayer meats. In February 2010, the Company announced that it has acquired the control of Cadbury plc. As of June 1, 2010, the Company owned 100% interest of Cadbury ADSs (Cadbury Shares).

Confident Investor comments: This is the last of Cramer’s “Diamonds of the Dow” companies and this one is decent as well. At this time, I think that a Confident Investor can cautiously invest in this stock as long as the price is correct. Most of the fundamentals of this company are good but there are some concerns.

Company name Alexion Pharmaceuticals, Inc.
Stock ticker ALXN
Live stock price [stckqut]ALXN[/stckqut]
P/E compared to competitors Fair
MANAGEMENT EXECUTION
Employee productivity Good
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Good
ANALYSIS
Confident Investor Rating Good
Target stock price (TWCA growth scenario) $88.56
Target stock price (averages with growth) $106.34
Target stock price (averages with no growth) $58.39
Target stock price (manual assumptions) $88.59

The following company description is from Google Finance: http://www.google.com/finance?q=alxn

Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the therapeutic areas of hematology, nephrology (including transplant rejection), neurology, ophthalmology and cancer. Alexion’s marketed product, Soliris (eculizumab), is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). On January 28, 2011, Alexion acquired Taligen Therapeutics, Inc. (Taligen). On February 10, 2011, Alexion acquired patents and assets from Germany-based Orphatec Pharmaceuticals GmbH (Orphatec) related to an investigational therapy for patients with Type A molybdenum cofactor deficiency (MoCD).

Confident Investor comments: This company’s growth rate could actually dictate a much higher price than I am conservatively giving it. At this price and at this time, I think that a Confident Investor can confidently invest in this stock.

As the United States breaks for a long weekend to commemorate our fallen soldiers in the variety of wars that we have engaged in over time, I thought it would be interesting to understand the investment philosophy of our elected leaders.

It didn’t take too long to be a little amazed. It seems that many of them do quite better than the average investor or the market at large.  There have been a couple of studies on this. While there is always the fear that this is due to insider knowledge or voting in ways to influence their portfolio, I am not sure those conclusions are valid.

In general, our elected officials tend to be a bit more educated than the average investor. Also, since they deal with corporations and massive budget items on a regular basis, they are more attuned to the market and the economy in general. Therefore, as an above average educated investor, it is not surprising that they beat the market.

Now I just wish that the elected officials performed as well at managing the public coffers that we elect them to manage!  Maybe we should give them a bonus if they do a good job. How about they get to split 1% of any budget surplus – how fast do you think they would balance the budget then?

Check out this Huffington Post article on this subject:

Members of the House of Representatives considerably outperform the stock market in their personal investments, according to a new academic study.

Four university researchers examined 16,000 common stock transactions made by approximately 300 House representatives from 1985 to 2001, and found what they call "significant positive abnormal returns," with portfolios based on congressional trades beating the market by about 6 percent annually.

What’s their secret? The report speculates, but does not conclude, it could have something to do with the ability members of Congress have to trade on non-public information or to vote their own pocketbooks — or both.

A study of senators by the same team of researchers five years ago found members of the higher chamber even better at beating the market — outperforming it by about 10 percent, an amount the academics said was "both economically large and statistically significant."

"Being one of 435, as opposed to one of 100, is likely to result in a significant dilution of power relative to members of the Senate," the researchers wrote.

The researchers, Alan J. Ziobrowski of Georgia State University, James W. Boyd of Lindenwood University, Ping Cheng of Florida Atlantic University and Brigitte J. Ziobrowski of Augusta State University, noted that the circumstances are ripe for abuse.

"In the course of performing their normal duties, members of Congress have access to non-public information that could have a substantial impact on certain businesses, industries or the economy as a whole. If used as the basis for common stock transactions, such information could yield significant personal trading profits," they wrote.

At the same time, House rules don’t require them to divest themselves of common stocks when they assume office, don’t prevent them from trading freely while in office — and don’t require them to recuse themselves from votes that could affect their own interests.

The House ethics manual clearly states that "all Members, officers, and employees are prohibited from improperly using their official positions for personal gain" and members must disclose their holdings annually.

But the House’s official position is that demanding that members either divest themselves of potential conflicts or recuse themselves when there is a conflict is "impractical or unreasonable" because it "could result in the disenfranchisement of a Member’s entire constituency on particular issues."

Ever since 2006, a small coterie of Democrats has been trying to officially prohibit members of Congress and their staffs from using non-public information to enrich their personal portfolios.

The Stop Trading on Congressional Knowledge (STOCK) Act was most recently re-introduced in March by Reps. Louise Slaughter (N.Y.) and Tim Walz (Minn.). It has not been heard from since.

The study found some significant difference based on party membership and seniority, with the Democratic sample beating the market by nearly 9% annually, versus only about 2% annually for the Republican sample.

And representatives with the least seniority considerably outperformed those with more seniority.

Why would that be? The researchers suspect need had something to do with it. "The financial condition of a freshman Congressman is far more precarious" than a senior member’s, they wrote. "House Members with the least seniority may have fewer opportunities to trade on privileged information, but they may be the most highly motivated to do so when the opportunities arise."

The report does not make any firm conclusions on causality, although the researchers explain that their kind of "event analysis" has become a common "method for analyzing whether actors have profited from confidential information in their possession."

* * * * *

Dan Froomkin is senior Washington correspondent for The Huffington Post. You can send him an email, bookmark his page; subscribe to his RSS feed, follow him on Twitter, friend him on Facebook, and/or become a fan and get email alerts when he writes.

I am continuously asked: Of all of the Good Companies that I list on this site, which are the best?

It is likely not in your best interest to invest in all of the companies that are Good Companies (which are re-listed for you in the Watch List). That strategy will spread your investment out too much and you will not be able to spend the time necessary to truly understand the companies and their operations. Instead you should focus on 10-20 companies that you can truly understand.

The best way to pick your investments is to diversify your companies into several industry segments (banking, retail, manufacturing, etc.) and that is why the Watch List is so long. It allows you to find several companies that are well run in any given industry segment.

But what if you didn’t care about diversification (perhaps because you satisfied this need via a diversified mutual fund strategy) and you just wanted the best of the best?

The Confident Investor Rating is a continuous integer rating scale. I break up that scale for this site into 3 segments: Poor, Fair, and Good. It is no surprise then that there are companies that are all the way at the top of that scale. The best of the Good Companies are:

  • Millicom International Cellular SA (USA) [stckqut]MICC[/stckqut]
  • Volterra Semiconductor Corporation [stckqut]VLTR[/stckqut]
  • Capital One Financial Corp. [stckqut]COF[/stckqut]
  • Image Sensing Systems, Inc. [stckqut]ISNS[/stckqut]

I think that every portfolio should include these 4 companies. They have consistently grown their EBIT, P/E, EPS and revenue over the last decade. They are simply excellent companies that score 10-20% higher than any other company on the Confident Investor Rating scale.

To be clear, Millicom and Voltera currently have a perfect score on the CIR scale and they are the only 2 companies that I am aware of that currently have that high of a score! Capital One and Image Sensing Systems are the only 2 companies that are currently one level below that perfect score. There are approximately 15 companies that make the next level after that.